TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (Nasdaq:RNAZ) (the “Company”), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the closing of its previously announced public offering of an aggregate of 5,942,623 shares of its common stock (or common stock equivalents) and warrants to purchase up to 11,885,246 shares of common stock at a combined public offering price of $1.22 per share (or per common stock equivalent) and accompanying warrants. The warrants have an exercise price of $1.22 per share, are exercisable immediately upon issuance and will expire three and one-half years from the date of issuance.

Read more at globenewswire.com